Table 2.
Pregnancy course follow-up according to country and study site
| Variable | Madagascar | Senegal | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall (n = 1,603) | Urban (n = 676) | Rural (n = 927) | P value* | Overall (n = 598) | Urban (n = 379) | Rural (n = 219) | P value* | |
| Pregnancy follow-up setting | ||||||||
| No. of antenatal consultations, median (IQR) | 3 (2–4) | 3 (2–4) | 4 (3–4) | < 0.0001 | 2 (1–3) | 2 (2–3) | 2 (1–3) | NS |
| Professional follow-up, n (%) | 1,589/1,602 (99) | 668/676 (99) | 921/926 (99) | NS | 557/563 (99) | 343/345 (99) | 214/218 (98) | NS |
| Antimicrobial consumption during pregnancy, n (%) | 214/1,435 (15) | 95/590 (16) | 119/845 (14) | NS | 39/454 (9) | 28/243 (11) | 12/211 (6) | 0.040 |
| Supplementation | ||||||||
| Iron supplementation, n (%) | 1,319/1,602 (82) | 498/675 (74) | 821/927 (89) | < 0.001 | 573/595 (96) | 366/377 (97) | 207/218 (95) | NS |
| Folate supplementation, n (%) | 1,260/1,594 (79) | 461/671 (69) | 799/923 (87) | < 0.001 | 415/574 (72) | 266/361 (74) | 149/213 (70) | NS |
| Malaria-related information | ||||||||
| IPTp-SP, n (%) | 844/1,603 (53) | 72/676 (11) | 772/927 (83) | < 0.001 | 460/592 (78) | 288/377 (76) | 172/215 (80) | NS |
| No. of IPTp-SP doses, median (IQR) | 1 (0–2) | 0 (0–0) | 2 (1–2) | < 0.0001 | 1 (1–1) | 1 (1–2) | 1 (1–1) | < 0.0001 |
| Mosquito net use, n (%) | 1,045/1,603 (65) | 296/676 (44) | 749/927 (81) | < 0.001 | 364/583 (62) | 173/376 (46) | 191/207 (92) | < 0.001 |
| Reported malaria cases, n (%) | 2 | 0 | 2 | – | 1 | 0 | 1 | – |
IPTp-SP = intermittent preventive treatment of malaria in pregnancy with sulfadoxine–pyrimethamine; IQR = interquartile range; NS = not significant. Bold values indicate statistically significant differences.
*
P values resulting from comparisons of urban and rural populations.